LONDON: RTW Biotech Opportunities Ltd (the “Company” or “RTW Bio”), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, announced aprivate portfolio company Amani Therapeutics (“Amani”) of the completion of a $25 million Series A financing.
Amani is a biotechnology company focused on developing highly efficacious and safer medicines for people living with serious neuropsychiatric disorders. RTW Bio invested $6.6 million in the Series A financing (in addition to $0.4 million invested in a previous SAFE funding that later converted to Series A shares), the total investment representing 0.8% of NAV as of 28 February 2026. Amani is the sixth new company creation of RTW Investments, LP.
Proceeds from the financing are expected to support the advancement of AM-01, a product comprising clozapine and an in-licensed Phase 3-ready component. AM-01 is designed to potentially deliver the efficacy of clozapine while addressing its most significant safety liability, severe neutropenia, a condition characterized by low levels of a type of neutrophils (white blood cells) in the blood.
Clozapine is the only therapy proven to meaningfully improve symptoms in treatment-resistant schizophrenia and to reduce suicide risk in patients with schizophrenia and schizoaffective disorder. However, its use remains limited due to safety concerns and the requirement for regular blood monitoring.
Rod Wong, CIO of RTW Investments, said, “We are pleased to support Amani Therapeutics in its mission to advance innovative treatments for neuropsychiatric disorders. The development of AM-01 represents a meaningful step forward towards addressing the significant unmet need in schizophrenia, and we believe Amani’s approach has the potential to transform the standard of care.”